06:23:29 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande


Inhalation Sciences Sweden, ISAB, är ett forskningsbolag. Idag innehas störst fokus mot framställning och utvecklande av laboratorieinstrument. Instrumenten används för att mäta partiklar i inandningsluften och hur luftens sammansättning påverkar lungorna. Bolaget säljer produkter under varierade varumärken, främst på den europeiska marknaden. Inhalation Sciences Sweden grundades 2004 och har sitt huvudkontor i Huddinge.


2022-11-22 Kvartalsrapport 2022-Q3
2022-08-29 Kvartalsrapport 2022-Q2
2022-06-08 Ordinarie utdelning ISAB 0.00 SEK
2022-05-23 Kvartalsrapport 2022-Q1
2022-05-06 Årsstämma 2022
2022-02-28 Bokslutskommuniké 2021
2021-11-24 Kvartalsrapport 2021-Q3
2021-08-26 Kvartalsrapport 2021-Q2
2021-06-22 Extra Bolagsstämma 2021
2021-06-09 Ordinarie utdelning ISAB 0.00 SEK
2021-06-08 Årsstämma 2021
2021-05-19 Kvartalsrapport 2021-Q1
2021-02-25 Bokslutskommuniké 2020
2020-11-26 Kvartalsrapport 2020-Q3
2020-08-26 Kvartalsrapport 2020-Q2
2020-06-12 Extra Bolagsstämma 2020
2020-05-13 Ordinarie utdelning ISAB 0.00 SEK
2020-05-12 Årsstämma 2020
2020-05-07 Kvartalsrapport 2020-Q1
2020-02-20 Bokslutskommuniké 2019
2019-11-14 Kvartalsrapport 2019-Q3
2019-08-22 Kvartalsrapport 2019-Q2
2019-05-22 Årsstämma 2019
2019-05-16 Kvartalsrapport 2019-Q1
2019-05-10 Ordinarie utdelning ISAB 0.00 SEK
2019-02-21 Bokslutskommuniké 2018
2018-12-13 Extra Bolagsstämma 2018
2018-11-15 Kvartalsrapport 2018-Q3
2018-08-22 Kvartalsrapport 2018-Q2
2018-05-24 Ordinarie utdelning ISAB 0.00 SEK
2018-05-23 Årsstämma 2018
2018-05-16 Kvartalsrapport 2018-Q1
2018-02-22 Bokslutskommuniké 2017
2017-11-17 Kvartalsrapport 2017-Q3
2017-08-28 Kvartalsrapport 2017-Q2
2022-04-11 08:30:00

(Stockholm, Sverige, 11 April 2022) Inhalation Sciences AB announces that its Annual Report 2021 is now available on the company's website. To read the whole Report (in Swedish), please visit: http://inhalation.se/investors/finansiella-rapporter/

Significant events during the reporting period
  • On February 10, ISAB announced that it has acquired an expanded internationally registered trademark for PreciseInhale® in strategic markets such as the United States, India and China.
  • On August 16, the company announced that the important patent for aerosol generation via PreciseInhale had been extended in the US until August 2034.
  • On October 12, ISAB announced its renewed collaboration with Karolinska Institutet regarding the validation of the new module XposeALI® MP (Micro Perfusion) in the Mars dust study.
  • On September 29, ISAB announced its collaboration with Redeye for company analysis and expanded collaboration regarding IR activities.
  • On November 25, ISAB announced that it has registered a trademark for PreciseInhale®, DissolvIt® and XposeALI® in the United States.
Significant events after the reporting period
  • On January 18, the company announced that it had sent an application for a study (white paper) to the FDA. This applies to DissolvIt® and to getting approved as a `Gold Standard' recommended dissolution method for inhalation studies.


The financial year 2021 continued to be another year with challenges surrounding COVID-19 and its effects on our operations. Despite the challenges and restrictions however we navigated the year efficiently and are proud to be able to summarize 2021 as a positive and successful year for Inhalation Sciences AB.

We achieved several major milestones in 2021, all of which lay a good foundation for our continued expansion:
  • Sales in the fourth quarter reached a peak of just over SEK 7,300,000 in sales orders received. We carried out some of these during the same period and will continue to work on invoicing our order backlog in the coming months.

  • The clinical study of PreciseInhale was successfully completed with demonstrated efficacy regarding 1) precise and accurate dosing (regional targeting) and 2) greater efficacy compared to a standard inhaler in a clinical setting. The study was completed on time and in budget and we are now preparing to chart the best possible way forward for the company in the clinical environment.

  • An application to the US Food and Drug Administration (FDA) was submitted in January 2022 with the goal of obtaining an FDA recommendation for our dissolution module DissolvIt® to be used in inhalation research and development. The application is the result of several months' dialogue with the FDA, and the market potential for DissolvIt®, following a possible FDA recommendation, is enormous, given that we are establishing the method as a new "Gold Standard method for Dissolution". This may well guide customers and research institutes in inhalation research and development towards the company.

In addition to achieving these important strategic goals, we have also continued to successfully reach new and existing customers in a focussed, goal-oriented way. The value of our sales pipeline and quotation requests has increased by 50% compared with the same period the previous year. We plan to further strengthen our commercial organization in early 2022.

Finally, the company has initiated an upgrade of our quality management system with the goal of becoming fully compatible with ISO 13485. This is a quality system that can be used by industry in both pre-clinical and clinical settings as demand for our products and services increases over time, driven by both regulatory standards and the expectations of our customers.

I look forward confidently to an exciting 2022 where we can continue to work based on our strategic plan, developing Inhalation Sciences AB, together with our customers, and increasing added value for both our partners and owners.

Huddinge April 11, 2022

Manoush Masarrat


To read full report (in Swedish) go HERE. (https://inhalation.se/investors/finansiella-rapporter/)